Eikon Therapeutics, Inc.

Eikon Therapeutics announced the dosing of the first patient in TeLuRide-008, a Phase 2/3 registrational study for EIK1001. This study evaluates EIK1001 in combination with pembrolizumab and chemotherapy as a first-line therapy for treatment-naïve patients with Stage 4 Non-Small Cell Lung Cancer (NSCLC). EIK1001 is designed to enhance immune response, and this marks a significant milestone as the company advances its pipeline to address unmet medical needs in oncology.

Eikon Therapeutics, Inc. announced the acceptance of seven abstracts for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. The presentations will cover updates across the company's clinical pipeline, including data from trials for EIK1001, EIK1003, EIK1004, and EIK1005. These updates include new data for EIK1001 in NSCLC, updated and initial data for EIK1003 in solid tumors and metastatic prostate cancer, initial results for EIK1004 in solid malignancies, and initial safety data for EIK1005.

Eikon Therapeutics, Inc. announced its upcoming inclusion in the broad-market Russell 3000® Index, effective after the US market closes on June 26, 2026. The Russell 3000 Index tracks approximately 3,000 stocks, representing 98% of the investable US equity market. This addition is expected to enhance the company's visibility among institutional investors.

Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. Ms. Francisco will also join the Compensation Committee. Her compensation package includes an annual retainer of $50,000 and an initial option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share, vesting monthly over four years.

Eikon Therapeutics announced updated clinical data for its lead programs, EIK1001 and EIK1003, presented at the 2026 ASCO Annual Meeting. The Phase 2 TeLuRide-005 trial for EIK1001 in NSCLC showed an overall objective response rate (ORR) of 63.1% and a disease control rate (DCR) of 90.8%, with a generally well-tolerated safety profile. The Phase 1/2 EIK1003 trial reported an ORR of 14.3% as monotherapy and 24.5% in combination with paclitaxel, demonstrating anti-tumor activity in advanced solid tumors.

Eikon Therapeutics announced positive updated clinical data for its lead programs, EIK1001 and EIK1003, presented at the 2026 ASCO Annual Meeting. The Phase 2 TeLuRide-005 trial for EIK1001 in NSCLC showed encouraging response rates and a favorable tolerability profile. Additionally, the Phase 1/2 trial for EIK1003, a PARP1 inhibitor, demonstrated antitumor activity as monotherapy and in combination with paclitaxel in advanced solid tumors, with a safety profile consistent with expectations. These results strengthen the case for continued development of both programs.

Eikon Therapeutics announced the publication of full-text abstracts for its lead clinical programs, EIK1001, EIK1003, and EIK1005, which will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The six accepted presentations will highlight updated clinical progress across the company's oncology pipeline, evaluating both monotherapy and combination strategies in patients with advanced diseases.

Eikon Therapeutics completed its initial public offering on February 6, 2026, raising approximately $348.1 million in net proceeds and converting all preferred stock into common stock, significantly improving its equity position. For the first quarter ended March 31, 2026, the company reported a net loss of $83.0 million, an increase from $68.2 million in the prior year. Despite the loss, Eikon believes its $596.0 million in cash, cash equivalents, and marketable securities will provide sufficient liquidity for at least one year.

Eikon Therapeutics reported a net loss of $83.0 million for the first quarter of 2026, an increase from $74.5 million in the prior-year period. Despite the increased loss, the company maintained a strong financial position with $596.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, expected to fund operations into the second half of 2027. The company also announced significant clinical progress, with six abstracts accepted for the ASCO annual meeting, highlighting new safety, tolerability, and efficacy data from its lead oncology programs EIK1001, EIK1003, and EIK1005.

Eikon Therapeutics reported a net loss of $83.0 million for Q1 2026, compared to $74.5 million in the prior year. The company maintained a strong financial position with $596.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, expecting to fund operations into H2 2027. Eikon also announced significant progress across its oncology pipeline, with six abstracts accepted for the ASCO annual meeting highlighting new data from its lead programs EIK1001, EIK1003, and EIK1005.